Artek Biotech was founded in 2019 and is a protein degradation drug developer. Focusing on a new small molecule adhesive drug for autophagy lysosome targeted degradation, we are committed to providing a new treatment plan for "untargeted" pathogenic proteins or "untreatable" targets. We have reserved multiple product pipelines under development and own independent intellectual property rights around major unmet clinical needs.